Financials

News Ideas Discussions Technicals Forecast Seasonals Options

MURA fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

MURA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company